EGFR and neoplasm: This is of special interest, since overexpression of EGFR has been associated with tumor development and poor prognosis in NSCLC [49, 50] and novel inhibitors of this signaling pathway such as cetuximab, erlotinib and gefitinib are of increasing clinical importance [51–54].